Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.61 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.55 |
| ▸ | PIM1 | P11309 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL671217 | 0.86 | CYP2A6 (0.74) | CYP2A6PIM3PIM1ALDH1A1CYP1A2 | |
| SCHEMBL2531595 | 0.85 | CYP2A6 (0.61) | CYP2A6PIM3PIM1ALDH1A1CYP1A2 | |
| SCHEMBL2535403 | 0.84 | PIM1 (0.53) | CYP2A6PIM3PIM1ALDH1A1CYP1A2 | |
| SCHEMBL15330695 | 0.84 | ALDH1A1 (0.53) | CYP2A6PIM3PIM1ALDH1A1CYP1A2 | |
| SCHEMBL15330072 | 0.84 | ALDH1A1 (0.56) | CYP2A6PIM3PIM1ALDH1A1CYP1A2 | |
| SCHEMBL29954562 | 0.83 | CCNT1 (0.58) | CYP2A6PIM3PIM1ALDH1A1CYP1A2 | |
| SCHEMBL12680496 | 0.82 | CCNT1 (0.48) | CYP2A6PIM3PIM1ALDH1A1CYP1A2 | |
| SCHEMBL15330831 | 0.80 | ALDH1A1 (0.52) | CYP2A6PIM3PIM1ALDH1A1CYP1A2 | |
| SCHEMBL2555126 | 0.80 | ERN1 (0.55) | CYP2A6ALDH1A1CYP1A2CYP2C19IMPDH2 | |
| SCHEMBL29955102 | 0.80 | ALDH1A1 (0.52) | CYP2A6PIM3PIM1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-8273744-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273744-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273744-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2240016-A1 | AMPK MODULATORS | Mercury Therapeutics, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100009992-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20100009992-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20100009992-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2010-01-14 | — | — | US | disclosed |
| WO-2009100130-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100130-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266892-A1 | AMPK Modulators | PRKAG1, PRKAG2, PRKAG3 | CYP2A6 1069/4885PIM3 2365/4885PIM1 2200/4885 |
| US-20120302576-A1 | AMPK MODULATORS | PRKAG1, PRKAG2, PRKAG3 | CYP2A6 1069/4885PIM3 2365/4885PIM1 2200/4885 |
| US-20100009992-A1 | AMPK MODULATORS | PRKAG1, PRKAG2, PRKAG3 | CYP2A6 1069/4885PIM3 2365/4885PIM1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.